Clinical review and case series reveals marked improvement across steroid-sensitive dermatoses without skin atrophy, indicating broad utility beyond atopic dermatitis.
Key Points
To review the pharmacodynamic mechanisms of tacrolimus ointment and evaluate the evidence supporting its clinical efficacy in dermatologic conditions beyond atopic dermatitis.
Synthesized pharmacodynamic data, randomized controlled trials, meta-analyses, and international clinical guidelines from the past 20 years.
Evaluated 6 clinical cases treated by dermatovenereologists across Russia, including discoid lupus erythematosus, rosacea, seborrheic dermatitis, facial allergic contact dermatitis, seborrheic psoriasis, and prurigo nodularis.
Tacrolimus selectively suppresses T-cell activation and cytokine synthesis while providing antipruritic effects and fungistatic activity against Malassezia spp., without inducing epidermal thinning or skin atrophy.
Identified an evidence base supporting off-label efficacy across more than 50 conditions, with inclusion in clinical guidelines for over 20 dermatologic entities.
Treatment across all 6 clinical cases produced marked clinical improvement and favorable tolerability, particularly in steroid-sensitive anatomic regions and patients with prior steroid dependence.